难治性2型糖尿病使用利拉鲁肽联合门冬胰岛素30治疗的临床疗效分析

Clinical efficacy analysis of liraglutide combined with insulin aspartate 30 in the treatment of refractory type 2 diabetes mellitus

目的探讨利拉鲁肽联合门冬胰岛素30治疗难治性2型糖尿病的临床疗效。方法80例难治性2型糖尿病患者,随机分为试验组和对照组,各40例。对照组患者采用门冬胰岛素30联合口服降糖药物进行治疗,试验组患者在对照组基础上联合利拉鲁肽进行治疗。比较两组患者治疗前后空腹血糖、餐后2 h血糖水平。结果治疗16个月后,试验组空腹血糖(7.11±1.30)mmol/L、餐后2 h血糖(7.75±2.30)mmol/L、均低于对照组的(8.63±1.20)、(9.20±2.31)mmol/L,差异有统计学意义(P<0.05)。结论采取利拉鲁肽联合门冬胰岛素30治疗难治性2型糖尿病效果显著,值得在临床推广。

Objective To discuss the clinical efficacy of liraglutide combined with insulin aspartate 30 in the treatment of refractory type 2 diabetes mellitus. Methods A total of 80 patients with refractory type 2 diabetes mellitus were randomly divided into experimental group and control group, with 40 cases in each group. The control group was treated with insulin aspartate 30 and administration of oral antidiabetic drugs, and the experimental group was treated with liraglutide on the basis of the control group. Comparison were made on changes of fasting blood glucose, postprandial 2 h blood glucose before and after treatment between the two groups. Results After 16 months of treatment, the experimental group had lower fasting blood glucose as(7.11± 1.30) mmol/L and postprandial 2 h blood glucose as(7.75±2.30) mmol/L than(8.63±1.20) mmol/L and(9.20±2.31) mmol/L in the control group. Their difference was statistically significant(P<0.05). Conclusion Liraglutide combined with insulin aspartate 30 shows remarkable effect in the treatment of refractory type 2 diabetes mellitus, and it is worthy of clinical promotion.